PRODEGRE

Based in Shanghai, China and founded in 2023, PRODEGRE (Shanghai) Pharmaceutical Co. , Ltd. , trading as PRODEGRE, is a major neurological disease mechanism research and innovative drug development company. In February 2026, PRODEGRE closed Angel+ funding led by new investor Furong Capital.

The company’s main business is the development of novel pharmaceuticals targeting major neurological diseases. The company’s self-developed products, leveraging a peptide-guided protein knockdown technology platform, are aimed at conditions such as Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS). The company generates revenues by providing research on the mechanisms of major neurological diseases and innovative medicines to the healthcare industry. The Angel+ funding raised in February 2026 will primarily be used to accelerate the development of the Prodegre ATLAS™ platform and to advance the first dosage form IND application and oral optimization work for the α-synuclein degradation agent, a key pathogenic protein in Parkinson's disease.